Wednesday, November 11, 2026

AI agents shift from answering questions to executing payments and military strikes

LLMs are evolving from passive information processors into autonomous agents that make decisions and take actions. MoonPay launched an AI payments platform in February 2026, while Claude AI helps identify and prioritize US military strike targets in Iran, marking a shift from Q&A systems to execution-capable agents.

AI agents shift from answering questions to executing payments and military strikes
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

MoonPay launched MoonPay Agents on February 24, 2026, enabling AI systems to execute cryptocurrency payments autonomously. The platform represents a shift from chatbots that answer questions to agents that complete transactions.

"Companies have AI that can answer questions, but not AI that can act," said Murali Swaminathan, highlighting the gap between current LLM capabilities and emerging autonomous systems. MoonPay Agents bridges this divide by giving AI models payment execution abilities.

Claude AI is helping identify targets and prioritize them for US strikes on Iran, MIT Technology Review reported. The deployment moves LLMs beyond information retrieval into military decision-making, where AI recommendations directly influence tactical operations.

Rad AI's technology transforms data chaos into actionable insights for healthcare providers, automating radiologist workflows rather than simply analyzing medical images. The system makes scheduling decisions and prioritizes cases without human intervention.

The shift from passive to agentic AI changes development priorities. Traditional LLMs optimize for accuracy and knowledge retrieval. Autonomous agents require decision-making frameworks, action execution capabilities, and safety constraints to prevent unintended consequences.

Payment processing, military targeting, and healthcare automation represent three distinct agent categories emerging in early 2026. Financial agents execute transactions, tactical agents recommend military actions, and workflow agents automate professional services.

Enterprise adoption requires new infrastructure. AI agents need API integrations to external systems, permission frameworks to limit action scope, and audit trails to track autonomous decisions. These requirements differ from chatbot deployments that only generate text responses.

Investment patterns are shifting toward agentic platforms. MoonPay Agents targets developers building AI applications that interact with financial systems, creating a new category beyond conversational AI tools.

The transition raises questions about liability and control. When an AI agent executes a payment or influences a military strike, accountability frameworks must determine responsibility for autonomous decisions. Current regulations treat AI as advisory tools, not decision-making entities.

Q1-Q2 2026 will test enterprise appetite for autonomous agents versus traditional LLMs. Early adoption in payments and military applications suggests high-stakes domains are moving fastest toward agentic AI, despite greater risks.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com